Lipids & metabolic liver disease
Comparative Effects of Emerging Lp(a)‐Lowering Agents and PCSK9 ‐Directed Therapies on Lipoprotein(a): A Network Meta‐Analysis of Randomised Clinical Trials
Authors' conclusion
Lp(a)-targeted therapies were associated with larger Lp(a) reductions than PCSK9-directed therapies, while PCSK9-directed therapies had greater LDL-C lowering.
Study context
- Population
- Adults (≥18 years) in RCTs with ≥8-week follow-up reporting Lp(a); databases searched through December 6, 2025
- Participants
- 17,810 adults51 trials
- Comparison
- Emerging Lp-targeted therapies vs PCSK9-directed therapies vs placebo
- Outcome
- Placebo-adjusted MD in percent change from baseline in Lp(a) (percentage points, pp)
Methodological detailsfrequentist random-effects network meta-analysis, P-score ranking, 16-node network
- Frequentist random-effects network meta-analysis
- P-score ranking
- 16-node network
Pooled result
As reported in the abstract
Placebo-adjusted MD in % change in Lp(a)
Each group vs placeboMD, pp (95% CI)
Olpasiran 225 mg Q12Wgreatest Lp(a) reduction
−98.94(−114.36 to −83.52)
- Evolocumab 140 mg Q2W
- MD −31.58 pp
Further pooled results
- PCSK9-directed therapies had greater LDL-C lowering than Lp(a)-targeted therapies
Safety
- No therapy was associated with higher serious adverse events (SAEs) or discontinuations vs placebo
- Alirocumab 150 mg was associated with more injection-site reactions
Original publication
Comparative Effects of Emerging Lp(a)‐Lowering Agents and PCSK9 ‐Directed Therapies on Lipoprotein(a): A Network Meta‐Analysis of Randomised Clinical Trials. Diabetes Obes Metab. Published 4 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →